

CLAIMS

What is claimed is:

1. A method of identifying a nucleic acid molecule suitable for use in a probe for detecting the presence of one or more of a family of nucleic acid molecules,
 - 5 comprising the steps of:
 - (a) providing the family of first nucleic acid molecules wherein each member of the family is related to all other members of the family by consensus sequence;
 - (b) providing a second nucleic acid molecule having a sequence
 - 10 complementary to the consensus sequence;
 - (c) determining the ability of the second nucleic acid molecule to form a duplex with each member of the family in the presence of a first ligand known to affect duplex formation of nucleic acid molecules;
 - (d) repeating step (c) for a plurality of concentrations of the ligand,
 - 15 wherein the nucleic acid molecule suitable for use in a probe is identified in step (c) at a ligand concentration at which the ability of the second nucleic acid molecule to form a duplex with each member of the family is substantially the same as its ability to form a duplex with each other member of the family.
 2. The method of claim 1, further comprising the step of (e) repeating steps (c) and
 - 20 (d) for a second ligand.
 3. The method of claim 2, further comprising the step of (f) repeating steps (c) and (d) in the presence of both first and second ligands.
 4. The method of claim 3 wherein step (e) is repeated for each of a plurality of the second ligands and step (f) is repeated for each of the second ligands or combinations
 - 25 thereof.
 5. The method of claim 1, further comprising the step of (g) determining the percent homology of the second nucleic acid sequence against a plurality of nucleic acid sequences in a database prior to step (c), wherein the second nucleic acid

sequence is less than a predetermined homology to other non-target partially complementary nucleic acid sequences.

6. The method of claim 1, wherein the first and second ligands are selected from the group consisting of actinomycin D, distamycin A, diminazane aceturate,

5 bisbenzimidazole, and ethidium bromide.

7. The method of claim 1, wherein said first nucleic acid molecules of the family are at least a% homologous with each other, a being a number greater than 0 and less than 100, comprising the further steps of:

(i) providing a third nucleic acid molecule which is no more than b%
10 homologous with each of the first nucleic acid molecules of the family, where b is a number greater than 0 and less than a;

(ii) repeating steps (c) and (d) in the presence of the third nucleic acid molecule so as to:

(a) determine the ability of the second nucleic acid molecule and
15 the third nucleic acid molecule to form a duplex with each other, and

(b) determine a ligand concentration at which the ability of the second nucleic acid molecule to form a duplex with the third nucleic acid molecule is substantially different from the ability of the second nucleic acid molecule to form a duplex with each other member of the family,

20 wherein the second nucleic acid molecule is suitable for use as a probe when the ligand concentration at which the ability of the second nucleic acid molecule to form a duplex with the third nucleic acid molecule is substantially different from the ability of the second nucleic acid molecule to form a duplex with each other member of the family and the ligand concentration at which the ability of the second nucleic acid molecule to form a duplex with each member of the family is substantially the
25 same as its ability to form a duplex with each other member of the family are substantially equal to each other.

8. The method of claim 7 wherein the second nucleic acid molecule is suitable for use as a probe when the ligand concentration at which the ability of the second nucleic acid molecule to form a duplex with the third nucleic acid molecule is substantially
30

- less than the ability of the second nucleic acid molecule to form a duplex with each other member of the family and the ligand concentration at which the ability of the second nucleic acid molecule to form a duplex with each member of the family is substantially the same as its ability to form a duplex with each other member of the family are substantially equal to each other.
9. The method of claim 7, further comprising the step of (e) repeating steps (c), (d), (i) and (ii) for a second ligand.
10. The method of claim 9, further comprising the steps of (c), (d), (i) and (ii) in the presence of both the first and second ligands.
11. The method of claim 1 wherein each of the first nucleic acid molecules is selected from a group consisting of a genetic sequence of a first virus and variants thereof known to exist in nature.
12. The method of claim 7 wherein each of the nucleic acid sequences of the first nucleic acid molecules is selected from a genetic sequence of a first virus and variants thereof, and the nucleic acid sequence of the third nucleic acid molecule is selected from a group of genetic sequences known to exist in nature exclusive of the first virus and the variants.
13. A probe having a nucleotide sequence of the second nucleic acid identified for use in a probe according to any preceding claim.
14. A method of detecting the presence of a nucleic acid molecule suspected of being in a sample containing genetic material, the method comprising:
- (A) providing the sample which contains or possibly contains a nucleic acid molecule which is a member of a family of first nucleic acid molecules that is related to all other members of the family by a consensus sequence;
 - (B) exposing the sample to a probe comprising a nucleotide sequence having a sequence complementary to the consensus sequence and identified according to the method of claim 1 as suitable for use in a probe, under conditions suitable for hybridization, in the presence of the ligand of claim 1

present at the concentration at which the ability of the second nucleic acid molecule to form a duplex with each member of the family is substantially the same as its ability to form a duplex with each other member of the family; and

- (C) ascertaining whether any duplexed nucleic acid molecules comprising the probe formed in step (C), wherein the formation of the duplexed nucleic acid molecules indicates the presence of the nucleic acid molecule suspected of being in the sample.

15. The method of claim 14, comprising the further step of exposing the same of step (B) to conditions suitable for amplifying the duplex formed in step (B).

16. A method of promoting the hybridization of a nucleic acid capture moiety to a target single-stranded nucleic acid sequence and all its family members without hybridizing to a plurality of other non-target partially complementary nucleic acid sequences present in a sample, the steps comprising:

(a) providing:

- (i) a nucleic acid capture moiety comprising the nucleic acid molecule identified in claim 5;
- (ii) the sample containing the target duplex nucleic acid sequence or any of its family members, wherein the sample has been treated such that all duplex nucleic acid sequences present in the sample including the target duplex nucleic acid sequence and all its family members suspected of being present in the sample will denature and form single-stranded nucleic acid sequences; and
- (iii) a nucleic acid sequence binding ligand;

- (b) forming a reaction mixture comprising the nucleic acid capture moiety, the sample and binding ligand of steps (a)(i), (a)(ii) and (a)(iii), respectively under conditions such that the nucleic acid sequence binding ligand promotes hybridization of the target single-stranded nucleic acid sequence and all its family members to the nucleic acid capture moiety comprising the probe nucleic acid sequence identified in step (a) and not to other non-target partially complementary nucleic acid sequences;

- (c) allowing the target single-stranded nucleic acid sequence and all its family members suspected of being present in a sample to hybridize to the nucleic

- acid capture moiety comprising the probe nucleic acid sequence identified in step (a) such that the nucleic acid sequence binding ligand promotes hybridization of the target single-stranded nucleic acid sequence and all its family members to the nucleic acid capture moiety comprising the probe nucleic acid sequence identified in step (a)
- 5 without promoting the hybridization of other non-target partially complementary nucleic acid sequences; and
- (d) detecting the presence or absence of the target single-stranded nucleic acid sequence and all its family members hybridized to the nucleic acid capture moiety.
- 10 17. A method of promoting the hybridization of a nucleic acid capture moiety to a target single-stranded nucleic acid sequence and all its family members without hybridizing to a plurality of other non-target partially complementary nucleic acid sequences contained in a sample, the steps comprising:
- (a) identifying at least one nucleic acid sequence probe substantially
- 15 complementary to the target duplex nucleic acid sequence and all its family members suspected of being present in a sample and coupling at least one probe nucleic acid sequence with a label;
- (b) identifying at least two substantially complementary primer nucleic acid sequences immediately 5' and 3' of the region of the target nucleic acid sequence and
- 20 all its family members to be detected;
- (c) treating the sample suspected of containing the target duplex nucleic acid sequences and all its family members with the two substantially complementary primer nucleic acid sequences in step (b), an agent for polymerization, and four nucleoside triphosphates under conditions which allow amplification of the nucleic
- 25 acid sequence to be detected thereof without simultaneous amplification of non-target partially complementary nucleic acid sequences from other viral nucleic acid sequences or human genomic nucleic acid sequences;
- (d) treating the sample such that all duplex nucleic acid sequences present in the sample including the amplified target duplex nucleic acid sequence and all its

family members suspected of being present in the sample denature and form single-stranded nucleic acid sequences;

(e) providing:

(i) a nucleic acid capture moiety comprising the labeled probe
nucleic acid sequence identified in claim 5;

(ii) the sample suspected of containing the amplified single-stranded target nucleic acid sequence and all its family members; and

(iii) a nucleic acid sequence binding ligand;

(f) forming a reaction mixture comprising:

(i) the nucleic acid capture moiety comprising the labeled probe
nucleic acid sequence identified in claim 5;

(ii) the sample suspected of containing the amplified single-stranded target nucleic acid sequence and all its family members; and

(iii) a nucleic acid sequence binding ligand;

under conditions such that the nucleic acid sequence binding ligand promotes hybridization of the amplified target single-stranded nucleic acid sequence and all its family members to the nucleic acid capture moiety comprising the probe nucleic acid sequence identified in step (a) and not to other non-target partially complementary nucleic acid sequences;

(g) allowing the amplified target single-stranded nucleic acid sequence and all its family members suspected of being present in a sample to hybridize to nucleic acid capture moiety comprising the probe nucleic acid sequence identified in step (a) such that the nucleic acid sequence binding ligand promotes hybridization of the target single-stranded nucleic acid sequence and all its family members to the nucleic acid capture moiety comprising the probe nucleic acid sequence identified in step (a) without promoting the hybridization of other non-target partially complementary nucleic acid sequences; and

(h) detecting the presence or absence of the target single-stranded nucleic acid sequence and all its family members hybridized to the nucleic acid capture moiety.

18. A hybridization mixture for promoting the hybridization of a nucleic acid capture moiety to a target single-stranded nucleic acid sequence and all its family members without hybridizing to a plurality of other non-target partially complementary nucleic acid sequences suspected of being present in a sample

5 comprising:

(a) a nucleic acid capture moiety comprising a labeled probe nucleic acid sequence substantially complementary to the target duplex nucleic acid sequence and all its family members suspected of being present in a sample;

(b) at least one nucleic acid sequence binding ligand, wherein the
10 ligand can promote hybridization of the target single-stranded nucleic acid sequence and all its family members to the nucleic acid capture moiety and not to other non-target partially complementary nucleic acid sequences.

19. The method of claim 17 wherein the nucleic acid sequence binding ligand is selected from the group consisting of: a compound which binds to a duplex nucleic acid in a sequence-specific way; a compound which binds to a duplex nucleic acid in a
15 non-specific way; a protein; an enzyme; an enzyme which alters the structure of a duplex nucleic acid to which it binds; an enzyme which alters the structure of a duplex nucleic acid to which it binds by breaking or forming a covalent or non-covalent bond, between an atom of the nucleic acid and another atom; an enzyme which cleaves one
20 or both strands of a duplex nucleic acid to which it binds; a restriction enzyme; a restriction endonuclease; an enzyme which methylates the duplex to which it binds; an enzyme which alkylates the duplex nucleic acid to which it binds; a nucleic acid ligase such as DNA ligase, an enzyme which promotes or catalyzes the synthesis of nucleic acid; a nucleic acid polymerase; a nucleic acid polymerase which requires a
25 double stranded primer; a DNA polymerase; DNA polymerase I; Taq polymerase; an RNA polymerase; an enzyme which alters the primary or secondary structure of a duplex nucleic acid to which it binds; a topoisomerase; an enzyme which promotes or inhibits recombination; a DNA binding agent; a mutagen; a compound which enhances the expression of a gene under the control of the duplex bound by a ligand; a
30 compound which interrelates into a duplex nucleic acid molecule; a compound which,

when contacted with a reaction mixture comprising a first single stranded nucleic acid molecule and a second single stranded nucleic acid molecule will increase the free energy of duplex formation at least n-fold, wherein n is 2, 5, 10, 50, 100, 500, 10^3 , 10^4 , 10^5 , 10^6 , a compound which, when contacted with a reaction mixture will decrease the free energy of duplex formation by at least n-fold, wherein n is 2, 5, 10, 50, 100, 500, 10^3 , 10^4 , 10^5 , 10^6 .

20. The hybridization mixture of claim 18, wherein the nucleic acid sequence binding ligand is selected from the group consisting of: a compound which binds to a duplex nucleic acid in a sequence-specific way; a compound which binds to a duplex nucleic acid in a non-specific way; a protein; an enzyme; an enzyme which alters the structure of a duplex nucleic acid to which it binds by breaking or forming a covalent or non-covalent bond, between an atom of the nucleic acid and another atom; an enzyme which cleaves one or both strands of a duplex nucleic acid to which it binds, a restriction enzyme; a restriction endonuclease; an enzyme which methylates the duplex to which it binds; an enzyme which alkylates the duplex nucleic acid to which it binds; a nucleic acid ligase such as DNA ligase; an enzyme which promotes or catalyzes the synthesis of nucleic acid; a nucleic acid polymerase; a nucleic acid polymerase which requires a double stranded primer; a DNA polymerase; DNA polymerase I; Taq polymerase, an RNA polymerase, an enzyme which alters the primary or secondary structure of a duplex nucleic acid to which it binds; a topoisomerase; an enzyme which promotes or inhibits recombination; a DNA binding agent; a mutagen; a compound which enhances the expression of a gene under the control of the duplex bound by a ligand; a compound which intercalates into a duplex nucleic acid molecule; a compound which, when contacted with a reaction mixture comprising a first single stranded nucleic acid molecule and a second single stranded nucleic acid molecule will increase the free energy of duplex formation at least n-fold, wherein n is 2, 5, 10, 50, 100, 500, 10^3 , 10^4 , 10^5 , 10^6 , a compound which, when contacted with a reaction mixture will decrease the free energy of duplex formation by at least n-fold, wherein n is 2, 5, 10, 50, 100, 500, 10^3 , 10^4 , 10^5 , 10^6 .

21. The method of claim 19, wherein the nucleic acid sequence binding ligand further comprises a single-stranded nucleic acid binding ligand.
22. The method of claim 19, wherein the nucleic acid sequence binding ligand further comprises a duplex nucleic acid sequence binding ligand.
- 5 23. The method of claim 19, wherein the nucleic acid sequence binding ligand further comprises a nonspecific nucleic acid binding ligand.
24. The method of claim 19, wherein the duplex nucleic acid sequence binding ligand is selected from the group consisting of actinomycin D, distamycin A, diminazene aceturate, bisbenzamide, and ethidium bromide.
- 10 25. The hybridization mixture of claim 20, wherein the nucleic acid sequence binding ligand further comprises a single-stranded nucleic acid binding ligand.
26. The hybridization mixture of claim 20, wherein the nucleic acid sequence binding ligand further comprises a duplex nucleic acid sequence binding ligand.
28. The hybridization mixture of claim 20, wherein the nucleic acid sequence
15 binding ligand further comprises a nonspecific nucleic acid binding ligand.
29. The hybridization mixture of claim 20, wherein the duplex nucleic acid sequence binding ligand is selected from the group consisting of actinomycin D, distamycin A, diminazene aceturate, bisbenzamide, and ethidium bromide.
30. The method of claim 17, wherein the nucleic acid capture moiety comprises a
20 structure A-B-C-D wherein:
 - A is a single-stranded nucleic acid sequence having a composition substantially complementary to a region of the target nucleic acid sequence and all its family members to be detected;
 - B and D are nucleic acid sequences which are capable of hybridizing to
25 each other to form an intramolecular duplex; and
 - C is a linker which covalently links B and D.
31. The hybridization mixture of claim 18, wherein the nucleic acid capture moiety comprises a structure A-B-C-D wherein:

A is a single-stranded nucleic acid sequence having a composition substantially complementary to a region of the target nucleic acid sequence and all its family members to be detected;

5 B and D are nucleic acid sequences which are capable of hybridizing to each other to form an intramolecular duplex; and

C is a linker which covalently links B and D.

32. The method of claim 17 or 18, wherein the target nucleic acid sequence is detected by means of a labeled probe nucleic acid sequence, wherein the label is selected from the group consisting of antibody, antigen, radioisotope, fluorescent,
10 enzyme, lectin or biotin.

33. The hybridization mixture of claim 19, wherein the label of the labeled probe nucleic acid sequence is selected from the group consisting of antibody, antigen, radioisotope, fluorescent, enzyme, lectin or biotin.

34. A kit for detecting the presence of a target nucleic acid sequence and all its
15 family members suspected of being present in a sample, the kit comprising:

(a) a nucleic acid capture moiety comprising a labeled probe nucleic acid sequence substantially complementary to the target duplex nucleic acid sequence and all its family members suspected of being present in a sample; and

(b) at least one nucleic acid sequence binding ligand, wherein the ligand can
20 promote hybridization of the target single-stranded nucleic acid sequence and all its family members to the nucleic acid capture moiety and not to other non-target partially complementary nucleic acid sequences.

34. The kit of claim 33, further comprising at least one component selected from the group consisting of a positive control containing one or more nucleic acid sequences
25 with a sequence of the target nucleic acid sequence and all its family members, a negative control which does not contain any nucleic acid sequences containing the sequence containing the suspected target nucleic acid sequence and all its family members.

35. The kit of claim 33, further comprising two substantially complementary primer nucleic acid sequences immediately 5' and 3' of the target nucleic acid sequence and all its family members, an agent for polymerization, and each of four nucleoside triphosphates.

5 36. The kit of claim 33, wherein the agent for polymerization is an enzyme selected from the group consisting of E. coli DNA polymerase 1, Klenow fragment of E. coli DNA polymerase, reverse transcriptase, or a thermostable DNA polymerase.

37. The kit of claim 33, wherein the target nucleic acid sequence and all its family members is a DNA sequence, the primer nucleic acid sequences are
10 oligodeoxyribonucleotides, and the nucleoside triphosphates are dATP, dCTP, dGTP, and dTTP.

38. The kit of claim 34, wherein the positive control is a region of viral nucleic acid sequence to be detected.

39. The kit of claim 38, wherein the viral nucleic acid sequence to be detected is a
15 region of the AIDS virus and all its family members.

40. The method of claim 17 wherein the target nucleic acid sequence and all its family members to be detected is a region of a viral nucleic acid sequence and all its family members.

41. The method of claim 40, wherein the region of viral nucleic acid to be detected
20 is a region of the AIDS virus and all its family members.

42. The method of claim 17, wherein the target nucleic acid sequence and all its family members to be detected is a region of an oncogene.

43. The method of claim 47, wherein the oncogene is selected from the group consisting of p53, ras, BRCA1, or BRCA2 and each of their family members.

25 44. The kit of claim 33, wherein the labeled probe nucleic acid sequence is selected from the group consisting of p53, ras, BRCA1, or BRCA2 and each of their family members.

45. The kit of claim 34, wherein the positive control is a region of the oncogene and all its family members to be detected.
46. The kit of claim 45, wherein the oncogene and all its family members to be detected is selected from the group consisting of p53, ras, BRCA1, BRCA2, or APC.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000